Medical device company Nexstim in Finland,has obtained CE mark approval for its non-invasive Navigated Brain therapy(NBT)system.
The system featuring MRI-based navigation allows users to visualize the electric field inside the patient's brain and accurately target therapy.
Using pulsed magnetic fields,the non-systemic therapeutic device stimulates a specific region of the cerebral cortex which is involved the controlling mood and associated with depression.
In addition,the therapy is also indicated for use in patients to recover from stroke,as a supplement to conventional rehabilitation.
Studies conduced on navigated brain therapy,for treating depression,has been shown to be safe,well-tolerated and without the side-effects associated with oral antidepressants.
The company said the NBT system has not received clearance from the FDA and is not available for sale in the US.
